{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:26:49Z","timestamp":1781155609212,"version":"3.54.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Moderate to severe osteogenesis imperfecta is associated with multiple fractures in childhood. There are no published data regarding the effects of third-generation bisphosphonates in these children. This randomized study investigated which of three different doses of risedronate was most effective in reducing fracture incidence. We randomly assigned 53 children with moderate to severe osteogenesis imperfecta to receive 0.2, 1, or 2 mg\/kg per week of risedronate. We assessed safety, fracture incidence, and bone measurement outcomes at 3, 6, 12, 18, and 24 months. At 24 months, 69% of children assigned 0.2 mg\/kg per week had had new fractures compared with 44% receiving 1 mg\/kg per week and 75% receiving 2 mg\/kg per week. Poisson regression with age and prior fracture as covariates showed that there was no difference in incident nonvertebral fracture between groups. Fracture rate diminished in each group during the trial compared with previous the 2 years (p\u2009=\u2009.005). Lumbar spine bone mineral density increased significantly (p\u2009=\u2009.009) only in the 2 mg\/kg per week group. Long bone bowing deformities reduced more in children receiving 1 or 2 mg\/kg per week of risedronate [odds ratio (OR) 0.67, 95% confidence interval (CI) 0.48\u20130.93 per unit increase in risedronate dose, p\u2009=\u2009.015]. There were no serious adverse events. Bone mass increased and bowing deformities reduced with increasing risedronate dose. Children suffered fewer fractures irrespective of risedronate dose. The most appropriate dose of risedronate for children with moderate to severe osteogenesis imperfecta in this study was 2 mg\/kg per week. \u00a9 2010 American Society for Bone and Mineral Research<\/jats:p>","DOI":"10.1359\/jbmr.090712","type":"journal-article","created":{"date-parts":[[2009,7,6]],"date-time":"2009-07-06T21:08:39Z","timestamp":1246914519000},"page":"32-40","source":"Crossref","is-referenced-by-count":53,"title":["A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta"],"prefix":"10.1093","volume":"25","author":[{"given":"Nick","family":"Bishop","sequence":"first","affiliation":[{"name":"Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdon"},{"name":"Academic Unit of Child Health, University of Sheffield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Harrison","sequence":"additional","affiliation":[{"name":"Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Royal Hospital for Sick Children, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Shaw","sequence":"additional","affiliation":[{"name":"Birmingham Children's NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Academic Unit of Bone Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Campbell","sequence":"additional","affiliation":[{"name":"ScHARR, University of Sheffield, Sheffield, United Kingdon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Knowles","sequence":"additional","affiliation":[{"name":"Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdon"},{"name":"Academic Unit of Child Health, University of Sheffield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hill","sequence":"additional","affiliation":[{"name":"Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hall","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Chapman","sequence":"additional","affiliation":[{"name":"Birmingham Children's NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Sprigg","sequence":"additional","affiliation":[{"name":"Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Rigby","sequence":"additional","affiliation":[{"name":"University of Hull, Hull, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"2024020401075383100_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11914-996-0025-2","article-title":"Treatment of children with osteogenesis imperfecta","volume":"4","author":"Rauch","year":"2006","journal-title":"Curr Osteoporos Rep."},{"key":"2024020401075383100_bib2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet."},{"key":"2024020401075383100_bib3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020401075383100_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020401075383100_bib5","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020401075383100_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00774-006-0706-z","article-title":"Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen","volume":"24","author":"Kishimoto","year":"2006","journal-title":"J Bone Miner Res."},{"key":"2024020401075383100_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S0007114507791924","article-title":"What do we currently know about nutrition and bone health in relation to United Kingdom public health policy with particular reference to calcium and vitamin D?","volume":"99","author":"Francis","year":"2008","journal-title":"Br J Nutr."},{"key":"2024020401075383100_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0169-6009(92)90712-M","article-title":"Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry","volume":"17","author":"Kroger","year":"1992","journal-title":"Bone Miner."},{"key":"2024020401075383100_bib9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med."},{"key":"2024020401075383100_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00003086-198109000-00012","article-title":"Systemic treatment of osteogenesis imperfecta","volume":"159","author":"Albright","year":"1981","journal-title":"Clin Orthop."},{"key":"2024020401075383100_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"2024020401075383100_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","article-title":"Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate","volume":"22","author":"Hosking","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020401075383100_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","article-title":"Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy","volume":"34","author":"Arikoski","year":"2004","journal-title":"Bone."},{"key":"2024020401075383100_bib14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020401075383100_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","article-title":"Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs","volume":"39","author":"Plotkin","year":"2006","journal-title":"Bone."},{"key":"2024020401075383100_bib16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child."},{"key":"2024020401075383100_bib17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone."},{"key":"2024020401075383100_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann NY Acad Sci."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.090712","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/25\/1\/32\/56578921\/jbmr90712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/25\/1\/32\/56578921\/jbmr90712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:53:03Z","timestamp":1710341583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/25\/1\/32-40\/7600281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1,20]]},"published-print":{"date-parts":[[2010,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.090712","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,1,1]]},"published":{"date-parts":[[2010,1,1]]}}}